Tilman Todenhöfer; Stefan Wirths; Claus Hann von Weyhern; Stefan Heckl; Marius Horger; Joerg Hennenlotter; Arnulf Stenzl; Lothar Kanz; Christian Schwentner In the present case, a combination of drugs ...

Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC). This is an ASCO Meeting Abstract from ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

There is currently no effective therapy for patients with advanced HLRCC-associated papillary renal cell carcinoma. Treatment with bevacizumab and erlotinib resulted in a confirmed response of 72% in ...

As the renal cell carcinoma (RCC) treatment landscape shifts to more personalized and combinatorial approaches, advanced practice providers (APPs) are key to the safety of patients receiving tyrosine ...

Moderate to advanced chronic kidney disease is an underappreciated burden of von Hippel-Lindau (VHL)-associated renal cell carcinoma (RCC) treated with surgery, which also includes frequent disease ...

A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, ...

Select patients with oligometastatic ccRCC might be managed with a period of metastasis-directed therapy alone. Serial metastasis-directed radiation therapy may delay systemic therapy in clear cell ...